Apexigen Inc. (APGN) can make a big difference with a little luck

Apexigen Inc. (NASDAQ: APGN) stock jumped 8.74% on Tuesday to $1.99 against a previous-day closing price of $1.83. With 0.7 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1500 whereas the lowest price it dropped to was $1.7600. The 52-week range on APGN shows that it touched its highest point at $31.35 and its lowest point at $0.61 during that stretch. It currently has a 1-year price target of $10.67.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APGN was up-trending over the past week, with a rise of 12.43%, but this was up by 145.07% over a month. Three-month performance dropped to -27.90% while six-month performance fell -80.00%. The stock lost -80.08% in the past year, while it has gained 191.79% so far this year. A look at the trailing 12-month EPS for APGN yields -1.59 with Next year EPS estimates of -1.33. For the next quarter, that number is -0.39. This implies an EPS growth rate of -19.90% for this year and 21.80% for next year.

Float and Shares Shorts:

At present, 22.57 million APGN shares are outstanding with a float of 20.74 million shares on hand for trading. On Dec 29, 2022, short shares totaled 16960.0, which was 0.08% higher than short shares on Nov 29, 2022. In addition to Dr. Xiaodong Yang M.D., Ph.D. as the firm’s Pres, CEO & Director, Ms. Amy Wong serves as its Sr. VP of Fin. & Operations.

Institutional Ownership:

Through their ownership of 19.74% of APGN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.77% of APGN, in contrast to 1.92% held by mutual funds. Shares owned by individuals account for 1.89%. As the largest shareholder in APGN with 1.12% of the stake, The Vanguard Group, Inc. holds 253,500 shares worth 253,500. A second-largest stockholder of APGN, BlackRock Fund Advisors, holds 213,833 shares, controlling over 0.95% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in APGN, holding 179,140 shares or 0.79% stake. With a 1.13% stake in APGN, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 253,880 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.41% of APGN stock, is the second-largest Mutual Fund holder. It holds 91,663 shares valued at 62514.0. Fidelity Total Market Index Fund holds 0.14% of the stake in APGN, owning 31,169 shares worth 21257.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, APGN reported revenue of $0.00 and operating income of -$1.78B. The EBITDA in the recently reported quarter was -$1.78B and diluted EPS was -$241.21.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APGN since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With APGN analysts setting a high price target of $15.00 and a low target of $8.00, the average target price over the next 12 months is $11.33. Based on these targets, APGN could surge 653.77% to reach the target high and rise by 302.01% to reach the target low. Reaching the average price target will result in a growth of 469.35% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.. Analysts have provided yearly estimates in a range of -$1.45 being high and -$1.79 being low. For APGN, this leads to a yearly average estimate of -$1.60. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Apexigen Inc. surprised analysts by -$0.13 when it reported -$0.41 EPS against a consensus estimate of -$0.28. Based on analyst estimates, the high estimate for the next quarter is -$0.26 and the low estimate is -$0.38. The average estimate for the next quarter is thus -$0.33.

Leave a Comment

Your email address will not be published. Required fields are marked *